These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19903812)

  • 61. Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance.
    Pritchard LK; Spencer DI; Royle L; Vasiljevic S; Krumm SA; Doores KJ; Crispin M
    J Virol; 2015 Jul; 89(13):6952-9. PubMed ID: 25878100
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies.
    Doria-Rose NA; Georgiev I; O'Dell S; Chuang GY; Staupe RP; McLellan JS; Gorman J; Pancera M; Bonsignori M; Haynes BF; Burton DR; Koff WC; Kwong PD; Mascola JR
    J Virol; 2012 Aug; 86(15):8319-23. PubMed ID: 22623764
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.
    Ren Y; Korom M; Truong R; Chan D; Huang SH; Kovacs CC; Benko E; Safrit JT; Lee J; Garbán H; Apps R; Goldstein H; Lynch RM; Jones RB
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209173
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.
    Wu X; Zhou T; Zhu J; Zhang B; Georgiev I; Wang C; Chen X; Longo NS; Louder M; McKee K; O'Dell S; Perfetto S; Schmidt SD; Shi W; Wu L; Yang Y; Yang ZY; Yang Z; Zhang Z; Bonsignori M; Crump JA; Kapiga SH; Sam NE; Haynes BF; Simek M; Burton DR; Koff WC; Doria-Rose NA; Connors M; ; Mullikin JC; Nabel GJ; Roederer M; Shapiro L; Kwong PD; Mascola JR
    Science; 2011 Sep; 333(6049):1593-602. PubMed ID: 21835983
    [TBL] [Abstract][Full Text] [Related]  

  • 65. AIDS/HIV. A boost for HIV vaccine design.
    Burton DR; Weiss RA
    Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840
    [No Abstract]   [Full Text] [Related]  

  • 66. A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01.
    Guo D; Shi X; Arledge KC; Song D; Jiang L; Fu L; Gong X; Zhang S; Wang X; Zhang L
    J Biol Chem; 2012 Dec; 287(51):43170-9. PubMed ID: 23100255
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker.
    Yuan W; Bazick J; Sodroski J
    J Virol; 2006 Jul; 80(14):6725-37. PubMed ID: 16809278
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.
    Doran RC; Morales JF; To B; Morin TJ; Theolis R; O'Rourke SM; Yu B; Mesa KA; Berman PW
    Mol Immunol; 2014 Nov; 62(1):219-226. PubMed ID: 25016576
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Development of a Stable MGAT1
    Doran RC; Yu B; Wright M; O'Rourke SM; Yin L; Richardson JM; Byrne G; Mesa KA; Berman PW
    Front Immunol; 2018; 9():2313. PubMed ID: 30344523
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains.
    Fera D; Schmidt AG; Haynes BF; Gao F; Liao HX; Kepler TB; Harrison SC
    Proc Natl Acad Sci U S A; 2014 Jul; 111(28):10275-80. PubMed ID: 24982157
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
    Caskey M; Klein F; Lorenzi JC; Seaman MS; West AP; Buckley N; Kremer G; Nogueira L; Braunschweig M; Scheid JF; Horwitz JA; Shimeliovich I; Ben-Avraham S; Witmer-Pack M; Platten M; Lehmann C; Burke LA; Hawthorne T; Gorelick RJ; Walker BD; Keler T; Gulick RM; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC
    Nature; 2015 Jun; 522(7557):487-91. PubMed ID: 25855300
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antibodies against Manalpha1,2-Manalpha1,2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains.
    Luallen RJ; Agrawal-Gamse C; Fu H; Smith DF; Doms RW; Geng Y
    Glycobiology; 2010 Mar; 20(3):280-6. PubMed ID: 19920089
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose.
    Stanfield RL; De Castro C; Marzaioli AM; Wilson IA; Pantophlet R
    Glycobiology; 2015 Apr; 25(4):412-9. PubMed ID: 25380763
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.
    Pejchal R; Doores KJ; Walker LM; Khayat R; Huang PS; Wang SK; Stanfield RL; Julien JP; Ramos A; Crispin M; Depetris R; Katpally U; Marozsan A; Cupo A; Maloveste S; Liu Y; McBride R; Ito Y; Sanders RW; Ogohara C; Paulson JC; Feizi T; Scanlan CN; Wong CH; Moore JP; Olson WC; Ward AB; Poignard P; Schief WR; Burton DR; Wilson IA
    Science; 2011 Nov; 334(6059):1097-103. PubMed ID: 21998254
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.
    Li L; Wang XH; Williams C; Volsky B; Steczko O; Seaman MS; Luthra K; Nyambi P; Nadas A; Giudicelli V; Lefranc MP; Zolla-Pazner S; Gorny MK
    Mol Immunol; 2015 Aug; 66(2):364-74. PubMed ID: 25965315
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates.
    Chakrabarti BK; Feng Y; Sharma SK; McKee K; Karlsson Hedestam GB; Labranche CC; Montefiori DC; Mascola JR; Wyatt RT
    J Virol; 2013 Dec; 87(24):13239-51. PubMed ID: 24067980
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies.
    Saphire EO; Montero M; Menendez A; van Houten NE; Irving MB; Pantophlet R; Zwick MB; Parren PW; Burton DR; Scott JK; Wilson IA
    J Mol Biol; 2007 Jun; 369(3):696-709. PubMed ID: 17445828
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
    Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
    J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope.
    Zhou T; Zheng A; Baxa U; Chuang GY; Georgiev IS; Kong R; O'Dell S; Shahzad-Ul-Hussan S; Shen CH; Tsybovsky Y; Bailer RT; Gift SK; Louder MK; McKee K; Rawi R; Stevenson CH; Stewart-Jones GBE; Taft JD; Waltari E; Yang Y; Zhang B; Shivatare SS; Shivatare VS; Lee CD; Wu CY; ; Mullikin JC; Bewley CA; Burton DR; Polonis VR; Shapiro L; Wong CH; Mascola JR; Kwong PD; Wu X
    Immunity; 2018 Mar; 48(3):500-513.e6. PubMed ID: 29548671
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
    Laman JD; Schellekens MM; Abacioglu YH; Lewis GK; Tersmette M; Fouchier RA; Langedijk JP; Claassen E; Boersma WJ
    J Virol; 1992 Mar; 66(3):1823-31. PubMed ID: 1637373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.